Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer

[1] E. Biecker, “Portal hypertension and gastrointestinal bleeding:

diagnosis, prevention and management,” World Journal of

Gastroenterology, vol. 19, no. 31, pp. 5035–5050, 2013.

[2] M. Takayama, S. Matsui, M. Kawasaki et al., “Efficacy of treatment with rebamipide for endoscopic submucosal dissectioninduced ulcers,” World Journal of Gastroenterology, vol. 19,

no. 34, pp. 5706–5712, 2013.

[3] J. Wang, X. Guo, C. Ye et al., “Efficacy and safety of proton

pump inhibitors (PPIs) plus rebamipide for endoscopic submucosal dissection-induced ulcers: a meta-analysis,” Internal

Medicine (Tokyo, Japan), vol. 53, no. 12, pp. 1243–1248, 2014.

[4] T. Ishida, O. Dohi, S. Yamada et al., “Clinical outcomes of

vonoprazan-treated patients after endoscopic submucosal dissection for gastric neoplasms: a prospective multicenter observation study,” Digestion, vol. 102, no. 3, pp. 386–396, 2021.

[5] C. P. Gyawali and R. Fass, “Management of gastroesophageal

reflux disease,” Gastroenterology, vol. 154, no. 2, pp. 302–318,

2018.

[6] I. Martínez-Hurtado, M. D. Arguisuelas, P. Almela-Notari

et al., “Effects of diaphragmatic myofascial release on gastroesophageal reflux disease: a preliminary randomized controlled trial,” Scientific Reports, vol. 9, no. 1, p. 7273, 2019.

[7] S. A. Shamsdin, M. Saberifiroozi, D. Mehrabani, and S. T. Heydari, “Pepsinogen I and II, gastrin and cag A serum levels in

Shiraz,” Middle East Journal of Digestive Diseases, vol. 3,

no. 2, pp. 103–109, 2011.

[8] H. P. Festen, J. C. Thijs, C. B. Lamers et al., “Effect of oral

omeprazole on serum gastrin and serum pepsinogen I levels,”

Gastroenterology, vol. 87, no. 5, pp. 1030–1034, 1984.

[9] K. Zhuang, Y. Yan, X. Zhang, J. Zhang, L. Zhang, and K. Han,

“Gastrin promotes the metastasis of gastric carcinoma through

the β-catenin/TCF-4 pathway,” Oncology Reports, vol. 36,

no. 3, pp. 1369–1376, 2016.

[10] G. Ferraro, B. Annibale, M. Marignani et al., “Effectiveness of

octreotide in controlling fasting hypergastrinemia and related

enterochromaffin-like cell growth,” The Journal of Clinical

Endocrinology and Metabolism, vol. 81, no. 2, pp. 677–683,

1996.

[11] M. Ito, K. Haruma, S. Kaya et al., “Serological comparison of

serum pepsinogen and anti-parietal cell antibody levels

between Japanese and German patients,” European Journal of

Gastroenterology & Hepatology, vol. 14, no. 2, pp. 123–127,

2002.

[12] T. Boda, M. Ito, M. Yoshihara et al., “Advanced method for

evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm,” Helicobacter, vol. 19, no. 1, pp. 1–8, 2014.

[13] K. Miki, M. Morita, M. Sasajima, R. Hoshina, E. Kanda, and

Y. Urita, “Usefulness of gastric cancer screening using the

serum pepsinogen test method,” The American Journal of Gastroenterology, vol. 98, no. 4, pp. 735–739, 2003.

[14] L. Agréus, T. Storskrubb, P. Aro, J. Ronkainen, N. J. Talley, and

P. Sipponen, “Clinical use of proton-pump inhibitors but not

H2-blockers or antacid/alginates raises the serum levels of

amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population,” Scandinavian Journal of Gastroenterology, vol. 44, no. 5, pp. 564–570, 2009.

[15] H. Mori, H. Suzuki, J. Matsuzaki et al., “Rifabutin-based 10day and 14-day triple therapy as a third-line and fourth-line

regimen for Helicobacter pylori eradication: a pilot study,”

United European Gastroenterology Journal, vol. 4, no. 3,

pp. 380–387, 2016.

[16] T. Iwao, A. Toyonaga, S. Kuboyama, and K. Tanikawa, “Effects

of omeprazole and lansoprazole on fasting and postprandial

serum gastrin and serum pepsinogen A and C,” Hepato-Gastroenterology, vol. 42, no. 5, pp. 677–682, 1995.

[17] M. Lazzaroni, O. Sangaletti, and G. Bianchi Porro, “Gastric

acid secretion and plasma gastrin during short-term treatment

with omeprazole and ranitidine in duodenal ulcer patients,”

Hepato-Gastroenterology, vol. 39, no. 4, pp. 366–370, 1992.

[18] A. Shiotani, R. Katsumata, K. Gouda et al., “Hypergastrinemia

in long-term use of proton pump inhibitors,” Digestion,

vol. 97, no. 2, pp. 154–162, 2018.

[19] H. Koop, M. Klein, and R. Arnold, “Serum gastrin levels during long-term omeprazole treatment,” Alimentary Pharmacology & Therapeutics, vol. 4, no. 2, pp. 131–138, 1990.

[20] S. A. Watson and A. M. Smith, “Hypergastrinemia promotes

adenoma progression in the APC (min-/+) mouse model of

familial adenomatous polyposis,” Cancer Research, vol. 61,

no. 2, pp. 625–631, 2001.

[21] C. Bordi, G. Cocconi, R. Togni, P. Vezzadini, and G. Missale,

“Gastric endocrine cell proliferation. Association with

Zollinger-Ellison syndrome,” Archives of Pathology, vol. 98,

no. 4, pp. 274–278, 1974.

[22] K. Iwakiri, Y. Sakurai, M. Shiino et al., “A randomized, doubleblind study to evaluate the acid-inhibitory effect of vonoprazan

(20 mg and 40 mg) in patients with proton-pump inhibitorresistant erosive esophagitis,” Therapeutic Advances in Gastroenterology, vol. 10, no. 6, pp. 439–451, 2017.

[23] N. Chapelle, P. Petryszyn, J. Blin et al., “A panel of stomachspecific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: a prospective, multicenter study in a low gastric

cancer incidence area,” Helicobacter, vol. 25, no. 5, article

e12727, 2020.

[24] B. Germaná, F. di Mario, L. G. Cavallaro et al., “Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti- Helicobacter pylori antibodies in the management of dyspeptic

patients in primary care,” Digestive and Liver Disease, vol. 37,

no. 7, pp. 501–508, 2005.

[25] H. Väänänen, M. Vauhkonen, T. Helske et al., “Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of

gastrin-17 and pepsinogen I: a multicentre study,” European

Journal of Gastroenterology & Hepatology, vol. 15, no. 8,

pp. 885–891, 2003.

[26] P. Sipponen, M. Härkönen, A. Alanko, and O. Suovaniemi,

“Diagnosis of atrophic gastritis from a serum sample,” Clinical

Laboratory, vol. 48, no. 9-10, pp. 505–515, 2002.

[27] E. Chueca, A. Lanas, and E. Piazuelo, “Role of gastrin-peptides

in Barrett's and colorectal carcinogenesis,” World Journal of

Gastroenterology, vol. 18, no. 45, pp. 6560–6570, 2012.

[28] A. Kokkola, P. Sipponen, H. Rautelin et al., “The effect of

Helicobacter pylori eradication on the natural course of

atrophic gastritis with dysplasia,” Alimentary Pharmacology

& Therapeutics, vol. 16, no. 3, pp. 515–520, 2002.

[29] H. Kishikawa, K. Kimura, A. Ito et al., “Cutoff pepsinogen level

for predicting unintendedly eradicated cases ofHelicobacter

pylori infection in subjects with seemingly normal pepsinogen

levels,” Digestion, vol. 95, no. 3, pp. 229–236, 2017.

Gastroenterology Research and Practice

...